Status:
COMPLETED
Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Conditions:
Fibroid Uterus
Eligibility:
FEMALE
18-64 years
Phase:
PHASE4
Brief Summary
The study team will be randomizing patients presenting for open myomectomy to either received transversus abdominal plane blocks with either liposomal bupivacaine or standard bupivacaine. The study te...
Detailed Description
After consent, patients will be randomized to either liposomal bupivacaine Transversus Abdominal Plane (TAP) vs standard bupivacaine TAP. Blocks will occur post induction and pre incision. Only the bl...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Not pregnant
- Weight over 50kg presenting for open myomectomy
- No history of allergy to any study medication
- No history of malignant ventricular dysrhythmia, epilepsy, seizure disorder, or chronic pain syndrome other than pain from myomas
- No history of drug or alcohol use or abuse disorder or pre-existing liver disease.
Exclusion
Key Trial Info
Start Date :
November 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 28 2025
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04272086
Start Date
November 9 2020
End Date
October 28 2025
Last Update
November 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029